Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Home Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

Response to Treatment with nab-Sirolimus in Patients with Perivascular Epithelioid Cell Sarcoma (PEComa) of Gynecologic or Peritoneal Origin: Subgroup Analysis from AMPECT

/ Publications

Share the Post

About the Author

Related Posts

PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa)
Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (nab-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer
Read More
Anupam Dalal, MD

Comments

Comments are closed.